Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vortioxetine 10 mg/day Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01163266
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
39
States / cities
Anaheim, California • Cerritos, California • Costa Mesa, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

NCT01491035
View directory record Official record
Conditions
Depressive Disorder, Anxiety Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Wichita, Kansas • Cincinnatti, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 30, 2026, 12:14 AM EDT
Recruiting Phase 4 Interventional

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

NCT07266545
View directory record Official record
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Vortioxetine, Cariprazine (Augmentation Phase)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

NCT01364649
View directory record Official record
Conditions
Treatment Outcome
Interventions
Vortioxetine, Escitalopram, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
53
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

Investigating the Effect of Vortioxetine in Adult ADHD Patients

NCT02327013
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Beverly Hills, California • Garden Grove, California • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 30, 2026, 12:14 AM EDT
Withdrawn Early Phase 1 Interventional

Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

NCT02454426
View directory record Official record
Conditions
Major Depressive Disorder, Coronary Artery Disease
Interventions
Vortioxetine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 4 Interventional Results available

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

NCT02371980
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00730691
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vortioxetine, Duloxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
66
States / cities
Anaheim, California • Beverly Hills, California • Fresno, California + 63 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00731120
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
40
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

NCT02709655
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Imperial, California • Lemon Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Sep 30, 2026, 12:14 AM EDT
Terminated Phase 3 Interventional Results available

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

NCT02871297
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 18 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Wichita, Kansas • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 4 Interventional Results available

Vortioxetine for Posttraumatic Stress Disorder

NCT02637895
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Placebo, Vortioxetine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training

NCT03272711
View directory record Official record
Conditions
Age-related Cognitive Decline
Interventions
Vortioxetine 10 mg, Cognitive training program
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 4 Interventional Results available

Vortioxetine for Menopausal Depression

NCT02234362
View directory record Official record
Conditions
Depression, Menopause, Vasomotor Disturbance, Hot Flashes, Sleep
Interventions
vortioxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

NCT02932904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vortioxetine, Paroxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years
Enrollment
361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
15
States / cities
Encino, California • Long Beach, California • Torrance, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Sep 30, 2026, 12:14 AM EDT
Not listed Phase 4 Interventional

Adjunctive Vortioxetine in Schizophrenia

NCT02357797
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms
Interventions
Vortioxetine, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Lauderdale Lakes, Florida • Grand Rapids, Michigan • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 4 Interventional Results available

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

NCT02972632
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Costa Mesa, California • Culver City, California • Glendale, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 30, 2026, 12:14 AM EDT
Terminated Phase 3 Interventional Results available

Vortioxetine to Prevent Return of Symptoms in Children With Depression

NCT05014919
View directory record Official record
Conditions
Depression
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Long Beach, California • Atlanta, Georgia • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Sep 30, 2026, 12:14 AM EDT
Withdrawn Phase 4 Interventional

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

NCT03580967
View directory record Official record
Conditions
Type2 Diabetes, Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Todd Doyle
Other
Eligibility
40 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

NCT01564862
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
vortioxetine (Lu AA21004), Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
62
States / cities
Tucson, Arizona • Little Rock, Arkansas • Bellflower, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT00707980
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 76 Years
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
38
States / cities
Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01179516
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
61
States / cities
Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 30, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

NCT02709746
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
12 Years to 17 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
42
States / cities
Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 30, 2026, 12:14 AM EDT